Houston-based Kiromic BioPharma shares begin trading

Kiromic calls itself a “target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.” The company’s primary technology can identify new cancer immunological targets for T cells and B cells.